echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Highlights of adjuvant therapy for NSCLC: T drug became the first and only approved adjuvant immune drug K drug Phase III clinical data released

    Highlights of adjuvant therapy for NSCLC: T drug became the first and only approved adjuvant immune drug K drug Phase III clinical data released

    • Last Update: 2022-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, many new advances have been made in the field of adjuvant therapy for non-small cell lung cancer (NSCLC)


    On March 16, the China National Medical Products Administration officially approved Roche's innovative tumor immunotherapy drug atezolizumab (trade name: Tecentriq®) as a single drug for the detection of tumor cells with an assessment of ≥1% ( TC) Adjuvant therapy for patients with stage II-IIIA non-small cell lung cancer with positive PD-L1 staining, surgical resection, and platinum-based chemotherapy[1]


    The results of the IMpower010 study showed that in patients with stage II-IIIA NSCLC whose tumors expressed PD-L1 ≥1%, atezolizumab was used as adjuvant therapy after surgery and chemotherapy, compared with the current best treatment.


    In October last year, Tecentriq became the first immuno-oncology drug approved by the US FDA for the adjuvant treatment of early-stage NSCLC [3]


    Recently, Merck announced the specific data of Keytruda in the adjuvant (postoperative) treatment of early-stage lung cancer


    The Phase 3 KEYNOTE-091 trial met one of the co-primary endpoints of disease-free survival (DFS) in the entire patient population regardless of tumor PD-L1 expression status, according to data presented at the European Society of Medical Oncology (ESMO) plenary meeting.


    In the data published by Merck, Keytruda had a disease-free survival benefit of 18% in patients with PD-L1 expression ≥50% (HR=0.


    How does Keytruda perform in subgroups of patients, especially those with stage IB or PD-L1-negative disease


    But so far, only "T" drugs have been officially approved for supplementary indications in China


    Reference source

    1.


    3.


    5.


    6.


    7.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.